Fibroblast growth factor 23 in patients undergoing peritoneal dialysis

Tamara Isakova, Huiliang Xie, Allison Barchi-Chung, Gabriela Varga, Nicole Sowden, Jessica Houston, Patricia Wahl, Andrew Lundquist, Michael Epstein, Kelsey Smith, Gabriel Contreras, Luis Ortega, Oliver Lenz, Patricia Briones, Phyllis Egbert, T. Alp Ikizler, Harald Jueppner, Myles Wolf

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background and objectives Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. Before FGF23 testing can be integrated into clinical practice of ESRD, further understanding of its determinants is needed. Design, setting, participants, & measurements In a study of 67 adults undergoing peritoneal dialysis, we tested the hypothesis that longer dialysis vintage and lower residual renal function and renal phosphate clearance are associated with higher FGF23. We also compared the monthly variability of FGF23 versus parathyroid hormone (PTH) and serum phosphate. Results In unadjusted analyses, FGF23 correlated with serum phosphate (r=0.66, P >0.001), residual renal function (r=0.37, P<0.002), dialysis vintage (r=-0.31, P=0.01), and renal phosphate clearance (r=-0.38, P=0.008). In adjusted analyses, absence of residual renal function and greater dialysis vintage associated with higher FGF23, independent of demographics, laboratory values, peritoneal dialysis modality and adequacy, and treatment with vitamin D analogs and phosphate binders. Urinary and dialysate FGF23 clearances were minimal. In three serial monthly measurements, within-subject variability accounted for only 10% of total FGF23 variability compared with 50% for PTH and 60% for serum phosphate.

Original languageEnglish
Pages (from-to)2688-2695
Number of pages8
JournalClinical Journal of the American Society of Nephrology
Volume6
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Peritoneal Dialysis
Phosphates
Kidney
Dialysis
Parathyroid Hormone
Chronic Kidney Failure
Serum
fibroblast growth factor 23
Dialysis Solutions
Vitamin D
Demography
Mortality

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Isakova, T., Xie, H., Barchi-Chung, A., Varga, G., Sowden, N., Houston, J., ... Wolf, M. (2011). Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clinical Journal of the American Society of Nephrology, 6(11), 2688-2695. https://doi.org/10.2215/CJN.04290511

Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. / Isakova, Tamara; Xie, Huiliang; Barchi-Chung, Allison; Varga, Gabriela; Sowden, Nicole; Houston, Jessica; Wahl, Patricia; Lundquist, Andrew; Epstein, Michael; Smith, Kelsey; Contreras, Gabriel; Ortega, Luis; Lenz, Oliver; Briones, Patricia; Egbert, Phyllis; Ikizler, T. Alp; Jueppner, Harald; Wolf, Myles.

In: Clinical Journal of the American Society of Nephrology, Vol. 6, No. 11, 01.11.2011, p. 2688-2695.

Research output: Contribution to journalArticle

Isakova, T, Xie, H, Barchi-Chung, A, Varga, G, Sowden, N, Houston, J, Wahl, P, Lundquist, A, Epstein, M, Smith, K, Contreras, G, Ortega, L, Lenz, O, Briones, P, Egbert, P, Ikizler, TA, Jueppner, H & Wolf, M 2011, 'Fibroblast growth factor 23 in patients undergoing peritoneal dialysis', Clinical Journal of the American Society of Nephrology, vol. 6, no. 11, pp. 2688-2695. https://doi.org/10.2215/CJN.04290511
Isakova, Tamara ; Xie, Huiliang ; Barchi-Chung, Allison ; Varga, Gabriela ; Sowden, Nicole ; Houston, Jessica ; Wahl, Patricia ; Lundquist, Andrew ; Epstein, Michael ; Smith, Kelsey ; Contreras, Gabriel ; Ortega, Luis ; Lenz, Oliver ; Briones, Patricia ; Egbert, Phyllis ; Ikizler, T. Alp ; Jueppner, Harald ; Wolf, Myles. / Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. In: Clinical Journal of the American Society of Nephrology. 2011 ; Vol. 6, No. 11. pp. 2688-2695.
@article{cc6985e7f5dd4e0a89c191d4e99299bb,
title = "Fibroblast growth factor 23 in patients undergoing peritoneal dialysis",
abstract = "Background and objectives Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. Before FGF23 testing can be integrated into clinical practice of ESRD, further understanding of its determinants is needed. Design, setting, participants, & measurements In a study of 67 adults undergoing peritoneal dialysis, we tested the hypothesis that longer dialysis vintage and lower residual renal function and renal phosphate clearance are associated with higher FGF23. We also compared the monthly variability of FGF23 versus parathyroid hormone (PTH) and serum phosphate. Results In unadjusted analyses, FGF23 correlated with serum phosphate (r=0.66, P >0.001), residual renal function (r=0.37, P<0.002), dialysis vintage (r=-0.31, P=0.01), and renal phosphate clearance (r=-0.38, P=0.008). In adjusted analyses, absence of residual renal function and greater dialysis vintage associated with higher FGF23, independent of demographics, laboratory values, peritoneal dialysis modality and adequacy, and treatment with vitamin D analogs and phosphate binders. Urinary and dialysate FGF23 clearances were minimal. In three serial monthly measurements, within-subject variability accounted for only 10{\%} of total FGF23 variability compared with 50{\%} for PTH and 60{\%} for serum phosphate.",
author = "Tamara Isakova and Huiliang Xie and Allison Barchi-Chung and Gabriela Varga and Nicole Sowden and Jessica Houston and Patricia Wahl and Andrew Lundquist and Michael Epstein and Kelsey Smith and Gabriel Contreras and Luis Ortega and Oliver Lenz and Patricia Briones and Phyllis Egbert and Ikizler, {T. Alp} and Harald Jueppner and Myles Wolf",
year = "2011",
month = "11",
day = "1",
doi = "10.2215/CJN.04290511",
language = "English",
volume = "6",
pages = "2688--2695",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "11",

}

TY - JOUR

T1 - Fibroblast growth factor 23 in patients undergoing peritoneal dialysis

AU - Isakova, Tamara

AU - Xie, Huiliang

AU - Barchi-Chung, Allison

AU - Varga, Gabriela

AU - Sowden, Nicole

AU - Houston, Jessica

AU - Wahl, Patricia

AU - Lundquist, Andrew

AU - Epstein, Michael

AU - Smith, Kelsey

AU - Contreras, Gabriel

AU - Ortega, Luis

AU - Lenz, Oliver

AU - Briones, Patricia

AU - Egbert, Phyllis

AU - Ikizler, T. Alp

AU - Jueppner, Harald

AU - Wolf, Myles

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background and objectives Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. Before FGF23 testing can be integrated into clinical practice of ESRD, further understanding of its determinants is needed. Design, setting, participants, & measurements In a study of 67 adults undergoing peritoneal dialysis, we tested the hypothesis that longer dialysis vintage and lower residual renal function and renal phosphate clearance are associated with higher FGF23. We also compared the monthly variability of FGF23 versus parathyroid hormone (PTH) and serum phosphate. Results In unadjusted analyses, FGF23 correlated with serum phosphate (r=0.66, P >0.001), residual renal function (r=0.37, P<0.002), dialysis vintage (r=-0.31, P=0.01), and renal phosphate clearance (r=-0.38, P=0.008). In adjusted analyses, absence of residual renal function and greater dialysis vintage associated with higher FGF23, independent of demographics, laboratory values, peritoneal dialysis modality and adequacy, and treatment with vitamin D analogs and phosphate binders. Urinary and dialysate FGF23 clearances were minimal. In three serial monthly measurements, within-subject variability accounted for only 10% of total FGF23 variability compared with 50% for PTH and 60% for serum phosphate.

AB - Background and objectives Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. Before FGF23 testing can be integrated into clinical practice of ESRD, further understanding of its determinants is needed. Design, setting, participants, & measurements In a study of 67 adults undergoing peritoneal dialysis, we tested the hypothesis that longer dialysis vintage and lower residual renal function and renal phosphate clearance are associated with higher FGF23. We also compared the monthly variability of FGF23 versus parathyroid hormone (PTH) and serum phosphate. Results In unadjusted analyses, FGF23 correlated with serum phosphate (r=0.66, P >0.001), residual renal function (r=0.37, P<0.002), dialysis vintage (r=-0.31, P=0.01), and renal phosphate clearance (r=-0.38, P=0.008). In adjusted analyses, absence of residual renal function and greater dialysis vintage associated with higher FGF23, independent of demographics, laboratory values, peritoneal dialysis modality and adequacy, and treatment with vitamin D analogs and phosphate binders. Urinary and dialysate FGF23 clearances were minimal. In three serial monthly measurements, within-subject variability accounted for only 10% of total FGF23 variability compared with 50% for PTH and 60% for serum phosphate.

UR - http://www.scopus.com/inward/record.url?scp=80655135433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80655135433&partnerID=8YFLogxK

U2 - 10.2215/CJN.04290511

DO - 10.2215/CJN.04290511

M3 - Article

C2 - 21903990

AN - SCOPUS:80655135433

VL - 6

SP - 2688

EP - 2695

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 11

ER -